SPINAL MUSCULAR ATROPHY

Spotlight Innovation has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.

PRESS RELEASES

MARCH 13, 2018
Newly Issued U.S. Patent Covers Spotlight Innovation’s Spinal Muscular Atrophy Drug Candidates

AUGUST 16, 2017
Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy

JUNE 30, 2017
Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy

JUNE 22, 2017
Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

FEBRUARY 8, 2017
Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182

OCTOBER 19, 2016
Spotlight Innovation Launches Development of STL-182 to Treat Spinal Muscular Atrophy